Aclarion Welcomes Advocate Health as CLARITY Trial Site
Advocate Health's Role in CLARITY Trial: Advocate Aurora Research Institute is participating in the CLARITY trial, which aims to evaluate Aclarion's Nociscan technology for improving surgical outcomes in patients with chronic low back pain by identifying painful discs through advanced diagnostic methods.
Nociscan Technology Overview: Nociscan utilizes Magnetic Resonance Spectroscopy and augmented intelligence to help physicians distinguish between painful and non-painful lumbar discs, potentially leading to better treatment strategies for the 266 million people suffering from chronic low back pain globally.
Trade with 70% Backtested Accuracy
Analyst Views on ACONW
No data
About the author
ACLARION SIGNS SECOND COMMERCIAL DEAL WITH WEILL CORNELL MEDICINE
- Announcement of Agreement: Aclarion has announced a second commercial agreement with Weill Cornell Medicine.
- Focus on Collaboration: The agreement aims to enhance collaboration in the field of medical technology and research.
ACLARION REVEALS PARTNERSHIP WITH WEILL CORNELL MEDICINE
Announcement of Agreement: Aclarion has announced a new agreement with Weill Cornell Medicine.
Collaboration Focus: The partnership aims to enhance medical research and innovation in healthcare.
Aclarion Names Dan Isherwood as UK Commercial Director to Enhance Adoption and Expand Market Reach
Aclarion's New Hire: Aclarion, Inc. has appointed Dan Isherwood as UK Commercial Director, marking a significant step in their commercial strategy to drive the adoption of their Nociscan technology for chronic low back pain.
Market Traction in the UK: Nociscan has gained strong traction in the UK, being reimbursed by three of the top four private insurers, which provides access to over 5.2 million covered lives, facilitating easier access for patients.
Nociscan Technology: Nociscan is an innovative SaaS platform that uses Magnetic Resonance Spectroscopy to help physicians differentiate between painful and nonpainful discs in the lumbar spine, potentially improving surgical outcomes.
Global Impact of Chronic Pain: Chronic low back pain affects an estimated 266 million people worldwide, highlighting the importance of Aclarion's technology in addressing this widespread health challenge.
Aclarion Recognized as "Rising Star" at 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Award Recognition: Aclarion, Inc. was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Awards, highlighting its innovative Nociscan solution for chronic low back pain among over 1,800 submissions.
Nociscan Technology: The Nociscan platform utilizes Magnetic Resonance Spectroscopy and AI algorithms to help physicians identify painful versus non-painful discs in the lumbar spine, aiming to improve treatment plans for the estimated 266 million people suffering from chronic low back pain globally.
Aclarion Unveils MR Spectroscopy Application for Detecting Discogenic Pain Biomarkers at Global Neuroscience Conference
Panel Discussion at ISPN Annual Meeting: Aclarion, Inc. participated in the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, focusing on the use of MR Spectroscopy to identify discogenic pain biomarkers, with insights from experts in the field.
Nociscan Technology: Aclarion's Nociscan® is a pioneering SaaS platform that utilizes MR spectroscopy and AI algorithms to help physicians differentiate between painful and non-painful lumbar discs, aiming to improve treatment strategies for chronic low back pain affecting over 266 million people globally.
Aclarion Recognized as a Finalist for the 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Recognition of Aclarion: Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards, highlighting its innovative approach to addressing chronic low back pain through its Nociscan technology.
Nociscan Technology: Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians differentiate between painful and non-painful lumbar discs, utilizing magnetic resonance spectroscopy and proprietary algorithms to provide actionable insights for personalized treatment plans.
ACLARION SIGNS SECOND COMMERCIAL DEAL WITH WEILL CORNELL MEDICINE
- Announcement of Agreement: Aclarion has announced a second commercial agreement with Weill Cornell Medicine.
- Focus on Collaboration: The agreement aims to enhance collaboration in the field of medical technology and research.
ACLARION REVEALS PARTNERSHIP WITH WEILL CORNELL MEDICINE
Announcement of Agreement: Aclarion has announced a new agreement with Weill Cornell Medicine.
Collaboration Focus: The partnership aims to enhance medical research and innovation in healthcare.
Aclarion Names Dan Isherwood as UK Commercial Director to Enhance Adoption and Expand Market Reach
Aclarion's New Hire: Aclarion, Inc. has appointed Dan Isherwood as UK Commercial Director, marking a significant step in their commercial strategy to drive the adoption of their Nociscan technology for chronic low back pain.
Market Traction in the UK: Nociscan has gained strong traction in the UK, being reimbursed by three of the top four private insurers, which provides access to over 5.2 million covered lives, facilitating easier access for patients.
Nociscan Technology: Nociscan is an innovative SaaS platform that uses Magnetic Resonance Spectroscopy to help physicians differentiate between painful and nonpainful discs in the lumbar spine, potentially improving surgical outcomes.
Global Impact of Chronic Pain: Chronic low back pain affects an estimated 266 million people worldwide, highlighting the importance of Aclarion's technology in addressing this widespread health challenge.
Aclarion Recognized as "Rising Star" at 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Award Recognition: Aclarion, Inc. was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Awards, highlighting its innovative Nociscan solution for chronic low back pain among over 1,800 submissions.
Nociscan Technology: The Nociscan platform utilizes Magnetic Resonance Spectroscopy and AI algorithms to help physicians identify painful versus non-painful discs in the lumbar spine, aiming to improve treatment plans for the estimated 266 million people suffering from chronic low back pain globally.
Aclarion Unveils MR Spectroscopy Application for Detecting Discogenic Pain Biomarkers at Global Neuroscience Conference
Panel Discussion at ISPN Annual Meeting: Aclarion, Inc. participated in the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, focusing on the use of MR Spectroscopy to identify discogenic pain biomarkers, with insights from experts in the field.
Nociscan Technology: Aclarion's Nociscan® is a pioneering SaaS platform that utilizes MR spectroscopy and AI algorithms to help physicians differentiate between painful and non-painful lumbar discs, aiming to improve treatment strategies for chronic low back pain affecting over 266 million people globally.
Aclarion Recognized as a Finalist for the 2025 Digital Health Awards by the Digital Health Hub Foundation at HLTH
Recognition of Aclarion: Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards, highlighting its innovative approach to addressing chronic low back pain through its Nociscan technology.
Nociscan Technology: Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians differentiate between painful and non-painful lumbar discs, utilizing magnetic resonance spectroscopy and proprietary algorithms to provide actionable insights for personalized treatment plans.
